ABBOTT LABORATORIES vs Johnson & Johnson, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where ABT and JNJ diverge most: on ev/ebitda, ABT reads 18.5 and JNJ reads 123.3; on p/b, ABT reads 3.30 and JNJ reads 7.51. The rest of the comparable metrics sit closer together. What ABT's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | ABT | JNJ |
|---|---|---|
| Price | $99.62 | $261.50 |
| Market cap | $174.0B | $638.1B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +8.8% | — |
| P/E | 27.9 | 30.4 |
| P/B | 3.30 | 7.51 |
| P/S | 3.86 | 6.52 |
| EV/EBITDA | 18.5 | 123.3 |
| Revenue growth | +6.6% | +8.1% |
| Gross margin | — | 68.2% |
| Operating margin | 12.1% | — |
| Net margin | 13.9% | 21.5% |
| Return on equity | 11.9% | 24.8% |
| Return on assets | 5.7% | 10.5% |
| Return on invested capital | 6.6% | — |
| FCF yield | 4.2% | 3.5% |
| Dividend yield | 2.4% | 2.0% |
| Debt / equity | 0.65 | 0.58 |
| Current ratio | 1.39 | 1.09 |
| Altman Z (solvency) | 7.16 | 5.01 |
| Piotroski F (quality) | 6 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.